Document is current
Any future updates will be listed below
-
Authors
Rieborn, Amy
Guchelaar, Niels A. D.
van Gelder, Teun
Gelderblom, Hans
Luelmo, Saskia A. C.
Kerssemakers, Nikki
Hamberg, Paul A. P.
Koolen, Stijn L. W.
Mathijssen, Ron H. J.
Moes, Dirk Jan A. R. https://orcid.org/0000-0003-3219-253X
van der Hulle, Tom
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05263245 at ClinicalTrials.govDocuments that mention this clinical trial
The Effect of Taking Cabozantinib with a Light Breakfast: A Randomized Crossover Pharmacokinetic Study (SKIPPY 1)
https://doi.org/10.1007/s40262-025-01612-2
- License Information
-
More Information
Article History
Received: 20 August 2025
Accepted: 14 December 2025
First Online: 19 January 2026
Declarations
:
: Ron Mathijssen received research funding during the previous 3 years from Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Deuter Oncology, Echo Pharmaceuticals, Nordic Pharma, Novartis, Pamgene, Pfizer, Roche, Sanofi, and Servier (all paid to the institute, and not related to the current article). In the previous 3 years, Teun van Gelder has received lecture fees and consulting fees from Roche Diagnostics, Thermo Fisher, Chiesi, Otsuka, Veloxis, CSL Behring, and Astellas (all paid to the institute). Teun van Gelder does not have employment or stock ownership at any of these companies, and neither does he have patents or patent applications. Paul Hamberg has received a consultant’s fee from Astellas, MSD, Pfizer AstraZeneca, BMS, and Ipsen. Teun van Gelder and Dirk Jan A.R. Moes are Editorial Board members of Clinical Pharmacokinetics . They were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Amy Rieborn, Niels A.D. Guchelaar, Hans Gelderblom, Saskia A.C. Luelmo, Nikki Kerssemakers, Stijn L.W. Koolen, and Tom van der Hulle have no conflicts of interest that are directly relevant to the content of this article.
: The study was approved by the local medical ethics committee (NL80085.058.22, METC Leiden Den Haag Delft), and was registered in ClinicalTrials.gov (NCT05263245) on 11 February, 2022. The study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.
: Patients signed an informed consent regarding publishing their data.
: Data and trial protocol can be shared upon reasonable request to the corresponding author.
: The code for analysis of the study data can be shared upon reasonable request to the corresponding author.
: AR, NADG, TvG, HG, SACL, NK, APH, SLWK, RHJM, DJARM, and TvdH wrote the manuscript; AR, NADG, RHJM, DJARM, and TvdH designed the research; AR, NADG, RHJM, DJARM, and TvdH performed the research; AR, DJARM, and TvdH analyzed the data.
